A new formulation of the opioid analgesic OxyContin is replacing existing Australian stocks of the medication from April 1. The new formulation is designed to prevent injecting.
While the change is intended to reduce risks associated with injecting prescription opioids, our experience demonstrates that it will create new risks, at least in the short term. Here is some brief harm reduction information for individuals, family members and workers.
Please share this information with anyone you think may need it.
Thanks to our colleagues at Sydney's Medically Supervised Injecting Centre, AIVL and WASUA who have kindly agreed to us sharing the preliminary information that they have developed. A more comprehensive resource will be available soon.